All In MedTech

Device Trial Radar · NCT07926386

Interventional Study to Describe the Utilization of Foam Dressings in Routine Clinical Practice, for the Treatment of Patients With Chronic Wounds in a Primary Healthcare Center in Italy.

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Jul 13, 2026

Primary completion

Dec 31, 2026

Study completion Mar 30, 2027

Sponsor

Lead sponsor
Molnlycke Health Care ABNot on our public-company list
Sponsor type
Industry
Collaborators
Niguarda Hospital
First posted
Nov 9, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will take place at the primary care center in Milan. Approximately forty outpatients with chronic wounds who are currently treated with a foam dressing will be screened according to predefined inclusion and exclusion criteria. Eligible patients will be enrolled and switched to Mepilex® Border Flex. They will then be followed for approximately 4 weeks after the dressing change, in line with routine clinical practice.

Conditions

  • Chronic Wound Care

Interventions

  • Mepilex Border FlexDevice

    Mepilex® Border Flex is designed for a wide range of exuding wounds such as pressure ulcers, leg and foot ulcers, traumatic wounds (e.g. skin tears) and surgical wounds. Mepilex® Border Flex can also be used on dry/necrotic wounds in combination with gels. Mepilex® Border Flex reduces postoperative blistering and may also be used as part of a prophylactic therapy to help prevent skin damage, e.g. pressure ulcers.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary ObjectiveTime frame: From enrollment to the end of treatment at appr 4 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Niguarda Hospital

    Milan, Niguarda, Italy · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.